EP3902917A4 - Compositions et méthodes pour le traitement du cancer - Google Patents
Compositions et méthodes pour le traitement du cancer Download PDFInfo
- Publication number
- EP3902917A4 EP3902917A4 EP19904756.4A EP19904756A EP3902917A4 EP 3902917 A4 EP3902917 A4 EP 3902917A4 EP 19904756 A EP19904756 A EP 19904756A EP 3902917 A4 EP3902917 A4 EP 3902917A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785592P | 2018-12-27 | 2018-12-27 | |
PCT/US2019/068423 WO2020139866A2 (fr) | 2018-12-27 | 2019-12-23 | Compositions et méthodes pour le traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3902917A2 EP3902917A2 (fr) | 2021-11-03 |
EP3902917A4 true EP3902917A4 (fr) | 2022-11-30 |
Family
ID=71129313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19904756.4A Pending EP3902917A4 (fr) | 2018-12-27 | 2019-12-23 | Compositions et méthodes pour le traitement du cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3902917A4 (fr) |
CN (1) | CN113508175A (fr) |
CA (1) | CA3163139A1 (fr) |
WO (1) | WO2020139866A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023277959A1 (fr) * | 2021-06-28 | 2023-01-05 | Bioaffinity Technologies, Inc. | Compositions et méthodes pour traiter le cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117657A2 (fr) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239270B1 (en) * | 1993-05-24 | 2001-05-29 | Rhone-Poulenc Rorer S.A. | Nucleic acids encoding human calcium sensor protein |
US20030004311A1 (en) * | 1997-06-18 | 2003-01-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
WO2001053455A2 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides associes |
US20080050393A1 (en) * | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
JP4865377B2 (ja) * | 2006-03-28 | 2012-02-01 | 国立大学法人 新潟大学 | ヒトメガリンの測定方法 |
US9044461B2 (en) * | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
CA2654010A1 (fr) * | 2006-06-02 | 2007-12-13 | Human Genetic Signatures Pty Ltd | Acide nucleique microbien modifie destine a la detection et a l'analyse de micro-organismes |
CA2681522A1 (fr) * | 2007-03-21 | 2008-09-25 | Raptor Pharmaceutical Inc. | Peptides des proteines rap cycliques |
WO2014165753A1 (fr) * | 2013-04-05 | 2014-10-09 | The Wistar Institute Of Anatomy And Biology | Méthodes et compositions de diagnostic d'un glioblastome ou d'un sous-type de glioblastome |
EP3325662B1 (fr) * | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Silençage épigénétique de nmt2 |
WO2017223273A1 (fr) * | 2016-06-22 | 2017-12-28 | President And Fellows Of Harvard College | Inhibition de cellules lymphoïdes innées de groupe 3 du côlon |
-
2019
- 2019-12-23 CN CN201980093039.3A patent/CN113508175A/zh active Pending
- 2019-12-23 CA CA3163139A patent/CA3163139A1/fr active Pending
- 2019-12-23 WO PCT/US2019/068423 patent/WO2020139866A2/fr unknown
- 2019-12-23 EP EP19904756.4A patent/EP3902917A4/fr active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117657A2 (fr) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine |
Non-Patent Citations (2)
Title |
---|
ANDERSEN RIKKE K. ET AL: "Melanoma tumors frequently acquire LRP2 /megalin expression, which modulates melanoma cell proliferation and survival rates", PIGMENT CELL & MELANOMA RESEARCH, vol. 28, no. 3, 14 January 2015 (2015-01-14), United States, Denmark, pages 267 - 280, XP055968578, ISSN: 1755-1471, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/pcmr.12352> DOI: 10.1111/pcmr.12352 * |
SHAO-CHIANG LAI ET AL: "Down-regulation of transcobalamin receptor TCblR/by siRNA inhibits cobalamin uptake and proliferation of cells in culture", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 317, no. 11, 25 February 2011 (2011-02-25), pages 1603 - 1607, XP028218051, ISSN: 0014-4827, [retrieved on 20110304], DOI: 10.1016/J.YEXCR.2011.02.016 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020139866A3 (fr) | 2020-10-15 |
CN113508175A (zh) | 2021-10-15 |
WO2020139866A2 (fr) | 2020-07-02 |
CA3163139A1 (fr) | 2020-07-02 |
EP3902917A2 (fr) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3947715A4 (fr) | Procédés et compositions pour le traitement du cancer | |
ZA202006627B (en) | Methods and compositions for treating cancer | |
EP3555077A4 (fr) | Compositions et procédés pour le traitement du cancer | |
EP3687981A4 (fr) | Compositions et méthodes de traitement du cancer | |
EP3983445A4 (fr) | Compositions et méthodes de traitement du cancer | |
EP3532464A4 (fr) | Compositions et procédés pour le traitement du cancer à médiation par l'ezh2 | |
EP3938354A4 (fr) | Compositions et méthodes de traitement du cancer | |
EP3612222A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3462883A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3600302A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3592346A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3528798A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3968785A4 (fr) | Compositions et méthodes de traitement du cancer | |
EP3908601A4 (fr) | Procédés et compositions pour le traitement du cancer | |
EP3541421A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3965896A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
SG11202012435UA (en) | Compositions and methods for treating cancer | |
EP4025590A4 (fr) | Procédés et compositions pour le traitement du cancer | |
EP3714043A4 (fr) | Compositions et méthodes pour traiter le cancer | |
EP3468546A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP4003351A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3585398A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3773585A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
IL286153A (en) | Methods and preparations for the treatment of cancer | |
EP3638293A4 (fr) | Méthodes et compositions pour le traitement du cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210727 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221027 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/713 20060101ALI20221021BHEP Ipc: C07K 14/705 20060101ALI20221021BHEP Ipc: C12N 15/113 20100101AFI20221021BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230508 |